Conference Details - Overview
Continuing Education Information
Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
New Developments in Lung and Head & Neck Cancers
Rosewood Crescent Hotel
Dallas, TX
September 25, 2008
Conference Overview
The New Developments in Lung and Head & Neck Cancers regional symposia are designed to update practicing oncologists and thoracic surgeons on recent advances in the management of lung and head & neck cancers, particularly those advances reported at major oncology meetings in 2008. Recent developments in the use of targeted agents, including anti-EGFR and antiangiogenic agents, in the treatment of NSCLC will be discussed. Additionally, efforts to individualize treatment according to histology and pharmacogenomics will be addressed. An overview of efforts to optimize chemotherapy for lung cancer will also be presented. In head and neck cancer, new approaches to improve systemic therapy through the use of predictive markers, targeted agents, and induction regimens will be discussed. Case-based discussions will be held, and there will be ample time for interaction with the faculty.
This educational program is directed toward medical oncologists, radiation oncologists, and thoracic surgeons specializing in lung and head & neck cancers. Fellows, oncology nurses, oncology physician assistants, and pharmacists in oncology who are interested in the treatment of these cancers are also invited to attend.
At the conclusion of this symposium, you should be able to:
- Discuss the efficacy of adjuvant chemotherapy for patients with early-stage NSCLC
- Evaluate the feasibility of pharmacogenomic profiling in selecting adjuvant therapy
- Summarize the efficacy and toxicity profile of treatment regimens utilizing targeted agents for locally advanced NSCLC
- Identify approaches to the optimal integration of antiangiogenic and anti-EGFR agents into therapy for metastatic NSCLC
- Discuss the role of single-agent chemotherapy immediately following a first-line doublet in metastatic NSCLC
- Assess the role of histology and biomarkers in predicting response to treatment in metastatic NSCLC
- Compare the survival benefit of various chemotherapy regimens in SCLC
- Describe novel molecular-targeted therapies that are being developed in lung cancer
- Discuss the efficacy and toxicity profile of treatment regimens for locally advanced and recurrent/metastatic head and neck cancer and biomarkers that predict response
- Assess the efficacy and safety of targeted agents in patients with head and neck cancer
Educational Grants
An educational grant for this activity was provided by:
- Genentech BioOncology/
OSI Oncology - Bristol-Myers Squibb/
ImClone Systems